Profile data is unavailable for this security.
About the company
Nordic Nanovector ASA is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
- Revenue in NOK (TTM)0.00
- Net income in NOK-434.14m
- Incorporated2009
- Employees40.00
- LocationNordic Nanovector ASAKjelsasveien 168 BOSLO 0884NorwayNOR
- Phone+47 22183301
- Fax+47 22580007
- Websitehttp://www.nordicnanovector.com/
More ▼
Mergers & acquisitions
| Acquired company | NANOV:OSL since announced | Transaction value |
|---|---|---|
| Apim Therapeutics As | -18.30% | -- |
| Apim Therapeutics As | -33.70% | 50.09m |
Data delayed at least 15 minutes, as of Feb 03 2023.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncozenge AB | 0.00 | -41.87m | 77.81m | -- | -- | 2.10 | -- | -- | -3.69 | -3.69 | 0.00 | 3.26 | 0.00 | -- | -- | -- | -69.60 | -- | -72.18 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -7.71m | 85.13m | -- | -- | 0.2845 | -- | -- | -0.0533 | -0.0533 | 0.00 | 1.09 | 0.00 | -- | -- | -- | -4.96 | -5.03 | -5.05 | -5.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.41 | -- | -52.37 | -- |
| Dextech Medical AB | 0.00 | -4.98m | 86.76m | 1.00 | -- | 2.35 | -- | -- | -0.2966 | -0.2966 | 0.00 | 2.06 | 0.00 | -- | -- | -- | -23.11 | -36.80 | -23.29 | -38.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.26 | -- | -18.38 | -- |
| PCI Biotech Holding ASA | 4.75m | -73.45m | 86.78m | 17.00 | -- | 1.37 | -- | 18.26 | -1.97 | -1.97 | 0.1273 | 1.70 | 0.0416 | -- | 0.5862 | 279,529.40 | -64.25 | -33.17 | -72.79 | -36.55 | -- | -- | -1,545.58 | -762.80 | -- | -- | 0.0221 | -- | -14.86 | -9.75 | -22.36 | -- | -- | -- |
| ISR Immune System Rgultn Hldg AB (publ) | 0.00 | -249.37m | 93.69m | -- | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | -2.39 | 0.00 | -- | -- | -- | -1,169.75 | -111.37 | -- | -155.17 | -- | -- | -- | -- | -- | -128,581.00 | -- | -- | -- | -- | -152.98 | -- | -- | -- |
| Lidds AB | 4.24m | -35.55m | 101.33m | 3.00 | -- | 2.23 | -- | 23.92 | -0.9805 | -0.9805 | 0.1166 | 0.6733 | 0.0874 | -- | 8.89 | -- | -73.34 | -18.73 | -88.78 | -19.85 | -- | -- | -839.40 | -878.39 | -- | -18,330.50 | 0.00 | -- | 930.15 | -- | -15.27 | -- | -29.79 | -- |
| Lipum AB (publ) | 0.00 | -52.60m | 103.91m | -- | -- | 23.78 | -- | -- | -11.98 | -11.98 | 0.00 | 0.5886 | 0.00 | -- | -- | -- | -144.61 | -- | -166.87 | -- | -- | -- | -- | -- | -- | -- | 0.3449 | -- | -100.00 | -- | -147.69 | -- | -- | -- |
| Nordic Nanovector ASA | 0.00 | -434.14m | 106.17m | 40.00 | -- | 0.5816 | -- | -- | -4.20 | -4.20 | 0.00 | 1.57 | 0.00 | -- | -- | 0.00 | -107.68 | -69.82 | -153.00 | -88.28 | -- | -- | -- | -636,940.80 | -- | -- | 0.00 | -- | -- | -- | -5.81 | -- | -29.60 | -- |
| Bioextrax AB publ | 529.36k | -15.30m | 106.52m | -- | -- | 4.44 | -- | 201.22 | -1.01 | -1.01 | 0.0347 | 0.971 | 0.0332 | -- | 3.26 | -- | -95.97 | -- | -123.03 | -- | -86.52 | -- | -2,890.40 | -- | -- | -22,539.96 | 0.00 | -- | 1,166.12 | -- | -89.02 | -- | -- | -- |
| Scandion Oncology A/S | -96.97bn | -96.97bn | 113.95m | -- | -- | 0.8982 | -- | -- | -- | -- | -- | 3.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0072 | -- | -- | -- | -217.81 | -- | -- | -- |
| Isofol Medical AB (publ) | 15.17m | -189.67m | 120.60m | 15.00 | -- | 0.6766 | -- | 7.95 | -4.22 | -4.22 | 0.124 | 1.14 | 0.0441 | -- | 1.17 | 1,043,000.00 | -55.10 | -61.04 | -69.25 | -74.66 | -1,086.11 | -- | -1,250.18 | -1,186.01 | -- | -- | 0.0023 | -- | -39.63 | -- | -5.96 | -- | -- | -- |
| Alzinova AB | 0.00 | -10.48m | 125.75m | -- | -- | 1.18 | -- | -- | -0.4388 | -0.4388 | 0.00 | 3.40 | 0.00 | -- | -- | -- | -10.34 | -8.30 | -10.66 | -8.62 | -- | -- | -- | -- | -- | -476.84 | 0.00 | -- | -- | -- | -16.19 | -- | 28.46 | -- |
| Toleranzia AB | 0.00 | -7.89m | 126.23m | -- | -- | 1.07 | -- | -- | -0.0673 | -0.0673 | 0.00 | 1.10 | 0.00 | -- | -- | -- | -6.19 | -12.63 | -6.43 | -13.30 | -- | -- | -- | -- | -- | -- | 0.0069 | -- | -- | -- | -27.68 | -- | 55.48 | -- |
| Peptonic Medical AB | 35.04m | -71.35m | 131.82m | -- | -- | 0.7808 | -- | 3.76 | -0.2277 | -0.2277 | 0.1075 | 0.1435 | 0.4188 | 1.04 | 3.39 | -- | -85.26 | -38.78 | -113.84 | -45.55 | 60.91 | -- | -203.61 | -223.58 | 0.5254 | -38.84 | 0.2223 | -- | -10.10 | -- | -115.39 | -- | -16.66 | -- |
| 2cureX AB | 7.76k | -27.99m | 133.14m | -- | -- | 2.71 | -- | 17,162.84 | -1.76 | -1.76 | 0.0005 | 2.88 | 0.0001 | -- | 0.0011 | -- | -42.42 | -23.18 | -44.73 | -27.65 | -176,600.00 | -88,517.02 | -360,787.50 | -94,872.34 | -- | -- | 0.00 | -- | -- | -- | -158.70 | -- | -37.81 | -- |
| Coegin Pharma AB | 0.00 | -34.52m | 133.51m | -- | -- | 5.64 | -- | -- | -0.0516 | -0.0516 | 0.00 | 0.0264 | 0.00 | -- | -- | -- | -142.04 | -- | -158.13 | -- | -- | -- | -- | -- | -- | -1,546.57 | 0.00 | -- | -- | -- | 41.29 | -- | -- | -- |
Data as of Feb 03 2023. Currency figures normalised to Nordic Nanovector ASA's reporting currency: Norwegian Krone NOK
13.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Folketrygdfondetas of 31 Dec 2021 | 7.82m | 6.74% |
| Fj�rde AP-fondenas of 31 Dec 2021 | 4.00m | 3.45% |
| Handelsbanken Fonder ABas of 31 Jan 2023 | 2.16m | 1.86% |
| Nordea Investment Management AB (Norway)as of 30 Jun 2022 | 895.05k | 0.77% |
| Storebrand Asset Management ASas of 31 Oct 2022 | 605.65k | 0.52% |
| Dimensional Fund Advisors LPas of 31 Oct 2022 | 376.39k | 0.32% |
| Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016 | 300.00k | 0.26% |
| Dimensional Fund Advisors Ltd.as of 31 May 2022 | 20.69k | 0.02% |
| SSgA Funds Management, Inc.as of 05 Jan 2023 | 1.36k | 0.00% |
| ATL 12 Capital Gesti�n SGIIC SAas of 30 Sep 2022 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2016 - 02 Feb 2023Source: FactSet Research Systems Inc.
